Brokerages Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) Target Price at $16.50

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have received an average rating of “Moderate Buy” from the seven research firms that are currently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $16.50.

Several research analysts have recently issued reports on NMRA shares. William Blair restated an “outperform” rating on shares of Neumora Therapeutics in a report on Wednesday, January 15th. Bank of America lowered their target price on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a report on Monday, January 6th. Royal Bank of Canada cut shares of Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and lowered their target price for the company from $29.00 to $4.00 in a report on Thursday, January 2nd. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price target on shares of Neumora Therapeutics in a research report on Thursday, January 2nd. Finally, JPMorgan Chase & Co. downgraded shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $18.00 to $15.00 in a research report on Tuesday, November 5th.

Neumora Therapeutics Stock Down 4.0 %

NASDAQ NMRA opened at $1.93 on Monday. Neumora Therapeutics has a 52 week low of $1.83 and a 52 week high of $21.00. The stock has a market capitalization of $311.81 million, a PE ratio of -1.03 and a beta of 2.71. The firm has a 50 day moving average of $7.24 and a two-hundred day moving average of $10.59.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). During the same period in the prior year, the business posted ($1.14) EPS. On average, equities research analysts expect that Neumora Therapeutics will post -1.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Neumora Therapeutics

A number of large investors have recently bought and sold shares of NMRA. JPMorgan Chase & Co. increased its holdings in shares of Neumora Therapeutics by 2.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 64,421 shares of the company’s stock valued at $851,000 after purchasing an additional 1,629 shares in the last quarter. Amalgamated Bank grew its stake in Neumora Therapeutics by 472.8% in the 2nd quarter. Amalgamated Bank now owns 2,910 shares of the company’s stock valued at $29,000 after acquiring an additional 2,402 shares during the last quarter. SkyOak Wealth LLC grew its stake in Neumora Therapeutics by 33.3% in the 4th quarter. SkyOak Wealth LLC now owns 20,000 shares of the company’s stock valued at $212,000 after acquiring an additional 5,000 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Neumora Therapeutics in the 4th quarter valued at about $61,000. Finally, Handelsbanken Fonder AB grew its stake in Neumora Therapeutics by 35.0% in the 3rd quarter. Handelsbanken Fonder AB now owns 26,600 shares of the company’s stock valued at $351,000 after acquiring an additional 6,900 shares during the last quarter. Hedge funds and other institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.